

Luo, Jian  
Application No.: 10/507,382

RECEIVED  
CENTRAL FAX CENTER  
JUL 21 2008

### Listing of Claims

1. (Currently Amended) A pharmaceutical composition ~~comprising~~ consisting of, as active agent, (1) a glucose-lowering agent metformin in one of its pharmaceutically acceptable forms, and (2) a lipid-improving agent selected from non-glucose-lowering fibrates, in combination with one or more pharmaceutically acceptable ingredients.
2. (Original) The pharmaceutical composition according to claim 1, wherein the non-glucose-lowering fibrate is selected from gemfibrozil and ciprofibrate.
3. (Original) The pharmaceutical composition according to claim 2, wherein the non-glucose-lowering fibrate is gemfibrozil.
4. (Currently Amended) The pharmaceutical composition according to claim 3, characterized by weight ratio of metformin or of its pharmaceutically acceptable form to gemfibrozil ranges from 1:0.1 to 1:10, ~~preferably from 1:0.5 to 1:2.~~
5. (Canceled).
6. (Canceled).
7. (Currently Amended) The pharmaceutical composition according to any one of claims 1-~~[[6]]~~ 4 or 11, wherein the glucose-lowering agent and the lipid-improving agent are mixed together to form an admixture and the admixture is administered to the mammal.

Luo, Jian  
Application No.: 10/507,382

8. (Currently Amended) The pharmaceutical composition according to any one of claims 1-~~[[6]]~~ 4 or 11, wherein the glucose-lowering agent and the lipid-improving agent are not mixed together but are administered independently to the mammal at about the same time.
9. (Currently Amended) A method to use the pharmaceutical composition in any one of claims 1-~~[[6]]~~ 4 or 11 for treating, controlling or preventing diseases, disorders or conditions selected from the group consisting of diabetes mellitus, hyperglycemia, impaired glucose-tolerance, insulin resistant syndrome, obesity, pancreatitis and other disorders where abnormality in plasma glucose levels or glucose metabolism is a component, comprising the administration of the said composition to human or non-human mammals.
10. (Original) The method according to claim 9, wherein the administration is by means of oral, inhalation, sublingual, buccal, intranasal, rectal, intravenous, subcutaneous, intramuscular, and transdermal administration.
11. (New) The pharmaceutical composition according to claim 3, characterized by weight ratio of metformin or of its pharmaceutically acceptable form to gemfibrozil ranges from 1:0.5 to 1:2.